Summary
We investigated the effects of estrogens on the regulation of dopamine receptors in the MtT/Wl5 transplantable rat pituitary tumor. Diethylstilbestrol (DES) and 17&estradiol treatment in female rats significantly decreased the number of dopamine binding sites (B,,,) from 85 k 3.9 fmol/mg protein in untreated rats to 9.2 k 1.2 and 8.2 + 2.8 fmol/mg protein in DES and 17/%estradiol-treated rats, respectively, while the binding affinities ( Kd) did not change significantly.
Testosterone treatment did not change the B,,,, while ovariectomy resulted in a significant increase in the B,,, (146.3 + 6.7 fmol/mg protein). The effects of DES on the B,,, were reversible, since removal of the DES for one week before sacrificing the animals led to a marked increase in the B,,, (54.9 f 3.1 fmol/mg protein).
Pituitaries from normal female rats treated with DES for 6 and 9 weeks had a significant decrease in the B max.
These results show that the number of dopamine binding sites in the membranes of MtT/WlS tumors is decreased by estrogen treatment and that this effect is reversible after removal of the estrogenic stimulus.
The MtT/WlS transplantable pituitary tumor which secretes PRL and GH was initiated by Furth et al. (1956) by diethylstilbestrol (DES) treatment in rats. Although this tumor was initially dependent on estrogens for growth, it subsequently became autonomous.
Recently reported that the MtT/WlS tumor had dopamine receptors, but that this tumor was refractory to dopaminergic inhibition of prolactin release. Earlier reports indicated that bromocriptine did not inhibit prolactin release from the MtT/WlS tumor (Lamberts and MacLeod, 1979) .
We have recently observed that the growth of the MtT/WlS tumor was inhibited by DES (Lloyd et al., 1985) . This observation was surprising in light of the origin of this tumor. However, other recent reports have indicated that growth of the MtTF4 transplantable pituitary tumor was also inhibited by estrogen . The MtTF4 pituitary tumor has recently been reported to have dopamine receptors which are down-regulated by 17b-estradiol treatment Albaladejo et al., 1984) . We previously noted that the DES inhibition of MtT/WlS tumor growth was associated with a relative increase in tumor for the presence of dopamine receptors and examined the regulation of these receptors by DES and several steroid hormones. The effects of DES on dopamine receptors in the MtT/WlS tumor were compared with the effects of DES on dopamine receptors in normal and in hyperplastic rat pituitary tissues after DES treatment.
Materials and methods

Animals
Forty-day-old Wistar-Furth female rats (Harlan, Madison, WI) were inoculated with 2 mm pieces of minced MtT/WlS tumor subcutaneously (s.c.) over the right lower flank. This tumor was obtained from Dr. Bogden at the Mason Research Institute (Worcester, MA) and has been maintained in our laboratory for 3 years with more than 20 passages. The tumors secrete large amounts of PRL and GH and contain immunoreactive PRL and GH in the cytoplasm (Lloyd et al., 1985) . Animals were exposed to a cycle of 12 h light and 12 h darkness. Food and water were available ad hbitum. Silastic tubes with 10 mg of DES, 17p-estradiol or testosterone were prepared as previously described (Lloyd et al., 1985) . Four weeks after tumor implantation 5 animals per group with palpable tumors were given 10 mg of DES. estrogen, or testosterone in Silastic tubes. Control animals received empty Silastic tubes. After various periods of treatment, animals were sacrificed by decapitation between 9 and 11 a.m. In some experiments after 1 week of DES treatment the Silastic tubes were removed under light anesthesia and these 5 animals were followed for one week before sacrificing.
Another group of 8 rats was ovariectomized one week after tumor implantation. These animals were subsequently sacrificed 6 weeks after ovariectomy.
Tumor tissues were used for dopamine receptor studies and for immunohistochemical studies. In other experiments groups of five 40-day-old Wistar-Furth female rats without tumors received 10 mg of DES in Silastic tubes. After 3, 6 and 9 weeks, the rats were sacrificed between 9 and 11 a.m. and the pituitaries were used for dop,amine receptors and immunohistochemical studies.
Dopumine receptor hiding studies
The MtT/WlS tumors and pituitary tissues were rapidly excised after decapitation. Tumor cells and pituitary tissues were separated from adjacent areas of necrosis and hemorrhage.
Sections of the tumors were fixed in neutral buffered formalin and stained with hematoxylin and eosin to confirm that non-necrotic pituitary tissue was present. The tissues were placed into ice-cold buffer (15 mM Tris, 120 mM NaCI, 5 mM KCl, 1 mM MgCl,, 2 mM CaCl,, 0.1 mM EDTA, 0.1% ascorbate and 12.5 PM nialamide, pH 7.3) which was used throughout the receptor study. The tissues were minced with sterile scalpel blades, transferred to fresh buffer (6 vols./wet weight) and homogenized with a Thomas Homogenizer 4 times for 60 s each time. The homogenate was filtered through 4 layers of cheesecloth then centrifuged at 1000 X g for 10 min at 4°C. The supernatant was centrifuged at 70000 x g for 60 min and the pellet was resuspended in ice-cold buffer and homogenized for 20 s. This homogenate was divided into samples and stored frozen at -80°C for 2 months or less with no apparent change in the dopamine receptor content. Aliquots were taken for protein determinations (8). The dopamine receptor assay was performed at 37°C using the procedure of Cronin et al. (1979 ranged from 0.6 to 0.9 mg/ml, and the total volume of the assay tube was 0.6 ml. After incubation at 37°C the samples had 3 ml of cold Tris buffer added. They were kept on ice 5-10 min before filtration and then washed 3 times with 3 ml of ice-cold buffer each time for 20-30 s. The radioactivity was trapped on Whatman GF/C filters and after drying for 2 h at 60°C was measured by liquid scintillation counting in Scintiverse (Fisher, Detroit, MI) with a machine counting efficiency of 30-40s.
Specific binding was defined as the difference between the radioactivity bound to the membranes in the absence (total binding) and in the presence of a lOOO-fold excess (2 PM) dbutaclamol (non-specific binding). The maximal number of binding sites (II,,,,) and the apparent dissociation constant ( K, ) were determined from Scatchard plots (Scatchard, 1949) 135 min at 37"C, but not with 0.25% ribonuclease. Specific binding as a function of incubation temperature for 30 min was shown to decrease in this order: 37"C, 23'C, 4°C and 60°C. The optimal pH for specific binding was 7.2, while pH 2 reduced specific binding to 20% of that seen at pH 7.2. All binding assays were done at 37°C for 30 min at pH 7.2. The protein concentration used in each assay was 0.6-0.9 mg/assay tube. With these conditions the specific binding represented from 40 to 82% of total binding. Specific binding did not change within the maximum 2-month period of storage of the homogenate at -80°C. A typical Scatchard plot is shown in Fig. 1 terone-, DES-and estradiol-treated groups were 0.61 k 0.13, 0.58 + 0.12, 0.67 + 0.12, 0.69 k 0.13 and 0.94 f 0.49 respectively.
To evaluate the reversibility of the down-regulation of dopamine receptors by DES, a group of 5 rats was treated with DES for one week. The DES was removed for one week before the animals were sacrificed and dopamine receptor levels measured. The B,,,, was 54.9 k 3 fmol/mg protein, while the K, was 0.90 f. 0.26, incidating that the dopamine receptor levels increased after removal of DES without any significant changes in the affinity for the receptor. Significant differences included * P < 0.05. ** P < 0.01 and *** Pi 0.001. CON, control; OVEX, ovariectomy;
TEST. testosterone; E17B, 17fi-estradiol; DES, diethylstilbestrol; DES DC, diethylstilbestrol discontinued for 1 week before sacrificing rats.
When the effects of estrogen on the non-tumorous pituitary were evaluated after DES treatment for zero, 3, 6 and 9 weeks, there was a significant decrease in dopamine receptor levels after 6 and 9 weeks of DES treatment (Fig. 3) . Although the B ,,,r,li was greater than that seen with the MtT/WlS tumors, the K, was in the same range with values of 0.84 + 0.19, 0.95 + 0.25, 0.52 + 0.28 and 0.83 + 0.23 in normal pituitaries and pituitary tissues after 3, 6 and 9 weeks of DES treatment respectively.
CON
DES DES DES 3wk 6wk 9wk Fig. 3 . The effects of various periods of DES treatment on the anterior pituitary gland dopaminergic binding capacity. Concentrations of ['Hlspiperone from 0.117 to 1.88 nM were used. Each value for binding capacity is the mean * SEM. The number of binding experiments is shown in parentheses.
Significant differences included * P < 0.05, ** P < 0.01 and *** P < 0.001.
Discussion
This study examines the effects of estrogen treatment on dopamine binding of [3H]spiperone to dopamine receptors of MtT/WlS tumor cell membranes.
DES and estrogen treatment resulted in a decrease of the maxima1 number of binding sites while the affinity for the receptor was not modified.
This effect was not seen with testosterone, which suggests that there is hormone specificity. The effects of estrogens on the dopamine receptor of MtT/WlS tumors is analogous to the effects of estradiol on the MtTF4 tumor dopamine receptor levels (Albaladejo et al., 1984) . However, the present study adds several new observations about the regulation of dopamine receptor levels in the MtT/WlS tumor. The first is that ovariectomy increases the B,,;,, of the tumor membrane.
We have previously shown that the MtT/Wl5 tumor grows at a slower rate after ovariectomy, indicating that a certain level of estrogen is still needed for optima1 growth of this tumor (Lloyd et al., 1985) . Heiman and BenJonathan (1982) noted that the B,,,,, in pituitaries from ovariectomized rats was high and subsequently decreased after estradiol treatment.
The second new observation in the present study is that discontinuation of the DES after one week resulted in increased levels of dopamine receptors. Silastic tubes with 10 mg of DES have been estimated to release approximately 45 pg/day of this estrogen (Wiklund et al., 1981) thus the animals are receiving a pharmacologic dose of estrogens. Not surprisingly dopamine receptors were not detected after 2 and 3 weeks of DES treatment. The subsequent rebound effect after removal of the DES suggests that the presence of dopamine receptors and inhibition of tumor growth by DES may be related in some way, since the tumor resumed growth when the DES was discontinued (Lloyd et al., 1985) . Alternatively, this relationship may be merely coincidental, since DES treatment in normal pituitary glands resulted in a decrease in dopamine receptors after 6 and 9 weeks in spite of continued proliferation of the pituitary cells (Lloyd, 1983) . Although the K, and K, values were higher than some reported values in the literature (Cronin et al., 1980) (Eljarmax et al., 1985) .
The MtT/WlS tumor has at least 2 cell populations, one producing GH and the other PRL although some of the cells may produce both PRL and GH (Parsons et al., 1978 (Parsons et al., , 1980 . Our recent experiments have shown that there is a shift in the population of GH and PRL cells after DES treatment with an increase in the GH-producing cells (Lloyd et al., 1985) . This latter observation may possibly explain the decrease in dopamine receptors if a population of GH cells without dopamine receptors constitutes most of the cell population in DES-treated rats. The alternate hypothesis that DES treatment resulted in a decrease in the number of dopamine receptors per cell in the tumor cannot be excluded.
The results seen in DEStreated normal pituitaries would support this latter view, because we and others have shown previously that there is an increase in the number of PRL cells after estrogen treatment in the normal pituitary gland (Lieberman et al., 1978; Lloyd, 1983) . The observation that ovariectomy results in increased dopamine receptor density and a slower rate of tumor growth while DES decreases dopamine receptor density but also slows tumor growth is somewhat paradoxical and might suggest that DES may have only partial agonist activity compared to 17P-estradiol. However most of the available evidence from in vitro studies of 17P-estradioland DES on the synthesis of prolactin by primary cultures of dispersed anterior pituitary cells indicates that DES is a complete agonist of 17/?-estradiol (Jordan and Lieberman, 1984) . The effects of chronic estrogen treatment on dopamine receptor levels have been quite variable Bression et al., 1983; Di Paolo and Falardeau, 1984) . Andre et al. (1982) did not find a significant decrease in the B,,,,, in pituitary dopamine receptors after 90 days of estradiol treatment.
Di Paolo and Falardeau (1984) found that after 25 weeks of estrogen treatment the B,,,.,, was not significantly decreased in estradiol-induced pituitary tumors, although bromocriptine did produce a decrease in the B,,,,,. Other workers (Bression et al., 1983) have found a significant decrease in the B,,,;,, with chronic estrogen treatment which agrees with our present report. The dopamine receptor has recently been identified in
